Reaction to the study analysing the effectiveness of Paxlovid against the omicron variant
A study published in the New England Journal of Medicine has analysed the effectiveness of the antiviral drug Paxlovid after implantation of the omicron variant. The relative risk of severe disease decreased markedly in patients over 65 years of age, both vaccinated and unvaccinated. No differences were found in those under 65 years of age.